# Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC

> **NCT05544253** · PHASE2,PHASE3 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 68 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Peritoneal Metastasis
- Hyperthymic
- HCC

## Interventions

- **PROCEDURE:** mitomycin C-based hyperthermic intraperitoneal chemotherapy

## Key facts

- **NCT ID:** NCT05544253
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05544253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05544253, "Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05544253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*